tiprankstipranks
In this article:
Blurbs

BTIG Keeps Their Buy Rating on RxSight (RXST)

In this article:
In this article:

BTIG analyst Ryan Zimmerman maintained a Buy rating on RxSight (RXSTResearch Report) today and set a price target of $24.00. The company’s shares closed last Wednesday at $12.10, close to its 52-week low of $11.19.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 22.8% and a 55.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Organogenesis Holdings, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for RxSight with a $20.60 average price target.

See the top stocks recommended by analysts >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

Read More on RXST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed